TEVA, US8816242098

Teva wins Weltruza approval. Barclays raises Teva stock target to USD 47

Published on 10/19/2026 at 10:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Weltruza's three-dose U.S. launch plan includes 318 mg, 425 mg and 531 mg. Barclays targets Teva stock at USD 47.00 ahead of November 3 results.

Weltruza approval and launch metrics

Teva received U.S. approval for Weltruza on October 9, 2026.
The treatment will launch in 318 mg, 425 mg and 531 mg doses.
Barclays set a USD 47.00 target for Teva stock before November 3 results.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries (ISIN US8816242098) secured U.S. approval for Weltruza on October 9, 2026, while Barclays set a USD 47.00 target for Teva stock. The regulatory decision gives the drugmaker a new branded-medicine launch ahead of its next quarterly update.

FDA approval adds three doses

According to Teva, the Food and Drug Administration approved Weltruza as a once-monthly subcutaneous olanzapine injection for adults with schizophrenia. The product is planned in three strengths: 318 mg, 425 mg and 531 mg, with no loading dose, oral supplementation or post-injection monitoring required.

The approval is based on the Phase 3 SOLARIS trial. The treatment's commercial contribution will depend on launch access, prescribing decisions and patient uptake once U.S. availability begins in the coming weeks, as Fierce Pharma reported on October 9, 2026.

What does the target imply?

Barclays raised its target for Teva stock to USD 47.00 from USD 42.00, according to TradingView. The target points to a valuation view that gives the Weltruza launch material importance, but it does not quantify future sales or market share.

Next results date is November 3

Gettex lists November 3, 2026 as the date for Teva's third-quarter financial results and an 8:00 a.m. ET conference call. That release should provide the next dated test of revenue trends, pipeline progress and management's launch commentary.

Valuation remains near yearly high

Teva's market capitalization was USD 48.4 billion on October 16, 2026. Its 52-week range was USD 18.83 to USD 42.02 on the same date, placing the stock's latest reported U.S. market level near the top of that range.